JOIN THE BNMS             


Twitter @BNMSnews

Updates from Industry

Blue Earth press release

Blue Earth Diagnostics continues to expand access to Axumin (fluciclovine (18F)) in Europe

Blue Earth Diagnostics continues to expand

Blue Earth Diagnostics’ latest press release - 17.04.19

Announcing the addition of Axumin® (fluciclovine (18F)) to the EAU guidelines for imaging in patients with biochemical recurrence in Prostate Cancer.

The aim of the EAU Guidelines is to assist practicing clinicians in making informed decisions in a given circumstance; taking the highest quality scientific data, their patient’s personal circumstances, values and preferences into account. This is great news for BED as it’s a clear recognition of the clinical value of Axumin in Europe.


Curium Brexit update - 12 April 2019

Please find attached the latest communication regarding Curium's Brexit Contingency plans.

Due to the recent approval of an extension until 31st October, Curium will revert back to Road freighting each day as of Sunday 14th April.

Customer Services in Portsmouth will work directly with customers to check their deliveries for next week and ensure they have the correct activity arriving on the correct day.

Curium Brexit update

Curium Communication - Brexit Contingency

Please find an update as of 18th March on behalf of Curium Pharma UK Ltd

Curium Brexit update

Blue Earth Diagnostics latest press release

See below Blue Earth Diagnostics’ latest press release announcing the first production and administration of Axumin® (fluciclovine (18F)) in Italy. This news demonstrates their continued commitment to maximize access to Axumin across Europe.

Press Release

Important Communication - LyoMAA & Pulmocis

Please find an important communication in relation to products LyoMAA & Pulmocis.

300119 Curium Pulmocis update

Brexit Update from Curium - updated

Please find the most recent information surrounding our Brexit contingency plans

Feb 2019 Curium Brexit Contigency updated